Cardiac b-adrenergic receptors (b-AR) are key regulators of cardiac haemodynamics and size. The scaffolding protein A-kinase anchoring protein 79/150 (AKAP5) is a key regulator of myocardial signalling by b-ARs. We examined the function of AKAP5 in regulating cardiac haemodynamics and size, and the role of b-ARs and Ca 2+ -regulated intracellular signalling pathways in this phenomenon.
Introduction
Activation of cardiac b-adrenergic receptors (b-ARs) by catecholamines promotes acute elevation of cyclic AMP, which results in chronotropic and inotropic effects on the heart muscle. A-kinase anchoring proteins (AKAPs) bind protein kinase A (PKA) and other proteins and compartmentalize them into signalling complexes. 1 Among the more than 50 AKAPs that have been identified, AKAP5 has attracted a significant attention. AKAP5 is widely expressed in the periphery and plays a major role in forming discrete signalling networks. AKAP5 binds to PKA, protein kinase C and calcineurin (CaN), and other signalling molecules, such as adenylyl cyclase (AC) 5/6, voltage-gated L-type calcium channels (LTCCs), and post-synaptic density forming proteins such as SAP97. 2, 3 A relationship between cardiac b 1 -ARs and AKAP5 was determined by immunohistochemical methods that revealed close association between post-synaptic b 1 -AR and AKAP5. 4, 5 Studies in cardiac myocytes derived from AKAP5 2/2 mice indicated that AKAP5 exerted effects on the regulation of Ca 2+ signalling and trafficking of the b 1 -AR. 6, 7 Nichols et al. to a subpopulation of LTCCs that were associated simultaneously with AKAP5 and cardiac caveolin 3. 7 Li et al. signalling in AKAP5 2/2 cardiac myocytes resulted in increased cardiomyocyte contractility and size in response to b 1 -agonists. In addition, intracellular trafficking of the b 1 -AR was impaired in AKAP5
2/2 cardiac myocytes and restored by the expression of AKAP5. These findings indicate that AKAP5 was a major AKAP involved in regulating the physiology and trafficking of cardiac b 1 -AR. 6 -8 In this study, we determined cardiac parameters in AKAP5 2/2 vs.
wild-type (WT) AKAP5 +/+ mice to determine the effect of global ablation of AKAP5 on cardiac function. Our results indicate that AKAP5 was actually cardioprotective, because its deletion was associated with significant cardiac hypertrophy and insufficiency that were reversed by the mixed a-and b-blocker carvedilol. These results are the first to indicate a clear role for an AKAP in cardiac remodelling and in regulating cardiac haemodynamics.
Methods

Mice and rats
AKAP5
+/+ and AKAP5 2/2 mice have previously been described. 7, 8 Animal experiments were performed according to protocols that were approved by the University of Tennessee-HSC Institutional Animal Care and Use Committee. Studies conformed to the 'Guide for Care and Use of Laboratory Animals' published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996). All mice were in the C57Bl6/J background and backcrossed .10 generations. Spargue -Dawley rats were used as the source of neonatal cardiac myocytes. Mice or rats were sacrificed by barbiturate overdose (pentobarbital, 150 mg/kg, i.p.).
Drug administration
One hour prior to placement of the Alzet mini-pump, each mouse received 0.125 mg/g of carprofen analgesic, i.p. Four-month-old mice were anaesthetized by inhalation of 2% isofluorane and the back area slightly posterior to the scapulae was shaved and wiped in betadine. A 0.5 cm skin incision was made and an Alzet model 2002 mini-pump that was filled with buffer (1% ascorbic acid in PBS) or isoprenaline (40 mg/kg/d) was inserted subcutaneously. The wound was closed with a 7 mm clip, followed by the application of triple antibiotic ointment. Pumps were removed 24 h before echocardiography following the same procedure used to implant them. Mouse chow containing placebo or carvedilol 1500 mg/kg was provided ad libitum to 4-month-old AKAP +/+ or AKAP5 2/2 mice for 10 days. 9,10 Cyclosporine A (CsA, 10 mg/kg) was injected i.p. daily for 2 weeks to matched littermates of 4-month-old AKAP5 +/+ or AKAP5 2/2 mice of either sex.
Echocardiography and histology
Mice were anaesthetized with isofluorane (2%) and placed on the recording stage of a Vevo 2100 ultrasound and imaged using an 18 -32 MHz MS400 transducer. The anterior chest was shaved and ultrasonic gel applied. Twodimensional images were recorded in parasternal long-and short-axis projections with guided M-mode recordings at the midventricular level in both views. M-mode echocardiographic measurements were obtained before and after each treatment.
Immunohistochemistry
After echocardiography, mice or rats were sacrificed by barbiturate overdose. Hearts were excised, cleaned, and embedded in tissue freezing medium at 2408C and sectioned. Eight-micron slices were adhered to silanated glass slides and stained with haematoxylin -eosin or Masson trichrome. Other tissue sections were permeabilized in 0.2% Triton X-100 in PBS for 10 min at 48C, incubated with anti-sarcomeric a-actinin and then incubated with a 1 : 100 dilution of rhodamine-conjugated goat anti-mouse (EMD Biosciences, San Diego, CA, USA), and analysed by immunocytochemistry.
Confocal recycling microscopy protocol
Cardiac myocytes were prepared from 1-day-old Sprague -Dawley rats and cultured on collagen-coated cover slips as described. 5, 6, 8 CaMKII (Cell Signaling Technology), followed by densitometric scanning of each band to determine optical density ratios.
Compromised cardiac function in AKAP5 KO mice
Immunoprecipitation
CaNa in pcDNA3.0 myc/His was ectopically expressed in HEK-293 cells with either empty p-EGFP-N1 or with AKAP5(321 -360)-GFP. 11 Cells were lysed and equal amounts of protein were subjected to affinitypurification on anti-AKAP5-IgG or pre-immune IgG beads. Then, equal volumes of eluate were probed for co-immunoprecipitation (IP) of CaNa by western blotting using anti-Myc (9E10) antibody (Santa Cruz Biotechnology) as described.
Statistical analysis
All data are expressed as mean + SE. The significance of differences between baseline and drug treatment within same genetic species and between pre-carvedilol and post-carvedilol echocardiographic values within the group was evaluated by Student's t-test. To evaluate differences in haemodynamic parameters among groups of transgenic mice, multigroup comparisons were made by two-way ANOVA followed by the Bonferroni post hoc test, using the Graph Pad Prism TM software. In addition, two-way ANOVA with Bonferroni correction for multiple comparisons was used to evaluate the morphometric measurements and enzymatic activities. Statistical significance was defined as P , 0.05.
Results
Ablation of AKAP5 leads to ventricular hypertrophy
AKAP5
2/2 mice did not display obvious anatomical, growth, or productive changes. 7 However, deletion of AKAP5 resulted in progressive ventricular hypertrophy ( Figure 1A and B). Histological sections confirmed enlarged left ventricular (LV) chambers in 3-month-old AKAP5 2/2 compared with AKAP5 +/+ mice and the enlargement progressed with age ( Figure 1A ). Body weights and left tibial lengths were not different, but there was a 16% increase (P , 0.05) in the ratio of heartto-body weight between AKAP5 2/2 and AKAP5 +/+ mice ( Figure 1B ).
These differences were apparent when heart weights were normalized to body weight showing a 16% increase in the ratios at 4 months (P , 0.05). Cross-sectional area of cardiac cells in AKAP5 2/2 mice at 4 months (679 + 100 mm 2 ) was significantly larger than the corresponding parameter (439 + 103 mm 2 ) in AKAP5 +/+ littermates ( Figure 1C and D). In addition, hearts from AKAP5 2/2 mice manifested ventricular myocyte interstitial fibrosis and increased collagen deposition ( Figure 1E and F ). Deletion of AKAP5 induced marked up-regulation in the expression of molecular markers of hypertrophy, 13 such as atrial and brain natriuretic peptides, and the ratio of b-to a-MHC ( Figure 1G ).
Loss of AKAP5 leads to compromised cardiac performance
Cardiac function was monitored by echocardiography in anaesthetized mice ( Figure 2A ). Loss of AKAP5 led to compromised cardiac function ( Figure 2B -F ). There was an age-dependent proportional decrease in systolic performance assessed as per cent ejection fraction from 65% in 4-month-old AKAP5 +/+ animals to 41% in matched AKAP5 2/2 littermates (P , 0.01). In addition, stroke volumes were significantly reduced (P , 0.05) in AKAP5 2/2 mice when compared with age-matched AKAP5 +/+ littermates ( Figure 2E ). Declines in cardiac function were associated with ventricular dilatation and a progressive increase in LV end-systolic and -diastolic dimensions ( Figure 2C and D) . An echocardiographic estimate of LV volume and necroscopic evaluation of heart-to-body weight indicated that loss of AKAP5 was associated with eccentric hypertrophy and dilatation. 14 
AKAP5 mice are resistant to stress-induced cardiac hypertrophy elicited by isoprenaline
Infusions of isoprenaline produce significant haemodynamic insufficiency, cardiac hypertrophy, and remodelling that is associated with significant apoptosis. 15, 16 To determine the role of AKAP5 in b-AR-induced cardiomyopathy, isoprenaline was infused for 10 days into AKAP5
2/2 and AKAP5 +/+ mice littermates ( Figure 3A) . In WT AKAP5 +/+ mice, isoprenaline led to 220 + 8% reduction in the ejection fraction (P , 0.05) and significantly increased systolic LV volume by 24 + 6% without affecting heart rate ( Figure 3A) . 17 In contrast, isoprenaline-mediated changes in cardiac function in AKAP5 2/2 mice were not statistically significant ( Figure 3A) . However, isoprenaline increased in the ratio of heart-tobody weight in AKAP5 +/+ or in AKAP5 2/2 mice by 1.5 + 0.18-fold (P , 0.05 compared with no drug treatment; Figure 3B ). Isoprenaline also increased the expression of hypertrophic markers, such as b-MHC, collagen-1a, and collagen-3a, by more than five-fold in AKAP5 +/+ and AKAP5 2/2 mice ( Figure 3C ).
3. CaMKII is associated with cardiac hypertrophy. 18 -20 To determine the effect of gene deletion of AKAP5 on the activity of cardiac CaN, AKAP5 2/2 mice were crossed with mice that expressed luciferase under the control of the NFAT nuclear transcription factor. 21 This approach is used to determine the activity of CaN in vivo because CaN dephosphorylates and activates cytosolic NFAT. 22 The activity of luciferase in cardiac extract from 4-month-old AKAP5 1/1 -NFAT-Luc Tg/? mice was 620 + 80 RLU/min/mg ( Figure 4A ). In age-and sex-matched AKAP5 knockout mice (AKAP5 2/2 -NFAT-Luc Tg/? mice), the activity of CaN as indexed by luciferase increased by an additional three-fold (P , 0.001). Similarly, total CaN phosphatase activity (okadaic acid-resistant and EGTA-sensitive) in AKAP5 2/2 cardiac extracts was significantly higher ) over dCaMKII, was elevated in cardiac homogenates prepared from ventricles of AKAP5 2/2 mice vs.
control mice ( Figure 4D) . Therefore, activities of CaN and CaMKII were both increased in hearts of AKAP5 2/2 mice. Compromised cardiac function in AKAP5 KO mice mammalian cells. 5, 8 These results were replicated in rat cardiac myocytes that expressed either the b 1 -AR or the b 2 -AR ( Figure 5A and B) . WT b 1 -AR or WT b 2 -AR (pseudo-red colour) was expressed on the surface of the cardiomyocyte and then internalized in response to isoprenaline ( Figure 5A , a and b, and B, p -q). Removal of isoprenaline promoted the recycling of internal b 1 -AR or b 2 -AR back into the myocardial cell membrane ( Figure 5A , c-e and B, r -t). Since the activity of CaN was increased in hearts of AKAP5 2/2 mice, we wondered whether altered CaN activity somehow affected the trafficking of these b-AR. Therefore, the effect of enhancing or suppressing the activity of CaN on trafficking of the b 1 -AR vs. the b 2 -AR was determined ( Figure 5A and B) . In cardiac myocytes that expressed constitutively active CaN, WT b 1 -AR or b 2 -AR was internalized and recycled normally ( Figure 5A , f -j, and B, u-y). Inhibition of CaN with FK-506 did not affect the internalization of WT b 1 -AR in response to isoprenaline, but inhibited its recycling ( Figure 5A, m-o) . In contrast, FK-506 had no effect on the internalization and recycling of WT b 2 -AR in rat cardiomyocytes ( Figure 5B , a ′ -e ′ ).
These findings are the first to show that inhibition of CaN differentially interfered with the trafficking of the b 1 -AR, but how this might occur is unknown. As outlined earlier, deletion of AKAP5 also interfered with were echoed before the placement of the Alzet mini-osmotic pump. Buffer (1% ascorbic acid in PBS) or isoprenaline (100 mg/mL of buffer) was infused by a model 2002 mini-osmotic pump at a rate of 0.5 mL/h for 10 days. Then, the pumps were removed and the mice were echoed the next day. The data were plotted as means + SE and then compared among different groups. (B) After the second echocardiography, mice were weighed and the heart was excised, weighed, and followed by extraction of RNA. (C) mRNA expression levels of hypertrophy markers were determined by quantitative RT-PCR. *P , 0.05 and **P , 0.01 represent the P-value of either base in WT vs. base in KO mice or isoprenaline in WT vs. isoprenaline in KO. volume in mL; (D) systolic LV volume in mL; (E) stroke volume in mL and heart rate in bpm. *P , 0.05, **P , 0.01, and ***P , 0.001 represent the P-value for either base in WT vs. base in KO mice.
recycling of the WT b 1 -AR in AKAP5 2/2 NMVM without affecting the trafficking of WT b 2 -AR in these cells. 8 Therefore, we wondered whether CaN bound to AKAP5 was primarily responsible for this selectivity. We addressed this question by repeating the recycling experiments in cells that expressed the WT b 1 -AR along with peptides that competed with endogenous CaN in binding to AKAP5 ( Figure 5C ). Plasmids harbouring the cDNA for a GFP-tagged peptide corresponding to the CaNbinding site between amino acids 321-360 of AKAP5 and another that expressed the core VIVIT sequence that binds avidly to CaN were used. 11, 12 Binding to AKAP5 was verified by co-IP's, where by ectopic expression of AKAP5 (312 -360)-GFP interfered with AKAP5 binding to CaN, while soluble GFP did not ( Figure 4D) . Expression of the empty GFP vector 'pseudo-green colour' did not interfere with the membranous localization, agonist-mediated internalization, or recycling of internal WT b 1 -AR 'pseudo-red colour' ( Figure 5C , f ′ -j ′ ). However, recycling of the agonist-internalized b 1 -AR was inhibited in cells that expressed the CaN-binding peptides ( Figure 5C , k ′ -o ′ and p ′ -t ′ ). These results along with the findings of Li et al. 8 indicate that CaN bound to AKAP5 was critical for recycling of cardiac b 1 -AR.
Reversal of the AKAP5
2/2 cardiac phenotype with carvedilol but not with CsA
To find out if the compromised cardiac performance associated with loss of AKAP5 bears similarities to cardiac insufficiency and failure in humans, we determined the effect of carvedilol on these parameters in age-matched AKAP5 +/+ vs. AKAP5 2/2 mice. Carvedilol is a nonselective b-blocker as well as an a 1 -AR blocker that is widely used in the management of heart failure in humans. 10 Carvedilol was administered to 4-month-old mice in chow at a concentration of 1500 p.p.m. for 10 days. 11 Echocardiography of WT AKAP5 +/+ mice before and after carvedilol indicated that this compound has no effect on haemodynamic parameters ( Figure 6 ). Echocardiography of AKAP5
2/2
littermates, however, showed a significant improvement in cardiac performance in both male and female mice ( Figure 6 ). Carvedilol increased the ejection fraction by 26 + 4%, markedly reduced systolic LV volumes by 43 + 8% in AKAP5 2/2 mice, and produced a 30 + 6% increase in the stroke volume ( Figure 6A ). In aggregate, these results indicate that haemodynamic parameters in AKAP5 2/2 after carvedilol were not significantly different from those in untreated AKAK5
Since ablation of the AKAP5 locus resulted in significant activation of CaN, we evaluated whether inhibition of CaN with CsA would affect the cardiac phenotype of AKAP5 2/2 mice ( Figure 4F) . Activities of CaMKII in heart homogenates of AKAP5 +/+ mice on regular chow or chow with carvedilol were . In (A -E), the P-value represents WT vs. KO. In (E), the P-value represents treatment with carvedilol vs. without carvedilol for each group.
Compromised cardiac function in AKAP5 KO mice 
2/2 mice on regular chow or chow containing carvedilol were 509 + 58 and 364 + 66 pmol/mg protein/min, respectively (P . 0.05). Therefore, the activity of CaMKII in carvedilol-fed AKAP5 2/2 mice was not significantly different from that of CaMKII in AKAP5 +/+ without or with carvedilol (P . 0.05). In addition, carvedilol normalized the activity of CaMKII ( Figure 4D ) and the ratio of heart-to-body weight ( Figure 6B ) in AKAP5 2/2 mice to its levels in AKAP5 +/+ mice. These results indicate that AKAP5 is cardioprotective by virtue of its inhibition of cardiac CaN and CaMKII signalling cascades and highlight a link between AKAP5 and cardiac b 1 -AR in this phenomenon.
Discussion
Role of AKAPs in cardiac physiology and pathology
Several approaches have been used to investigate the role of the more than 14 cardiac AKAPs in regulating a variety of cardiac events. Knockdown of muscle AKAPb with an siRNA in cardiac myocytes inhibited a-and b-adrenergic agonist-induced hypertrophy. 23 siRNA-mediated knockdown of cardiac Yotiao (AKAP9) indicated that this AKAP was involved in regulating the activity of cardiac potassium channels and b-adrenergic signalling. 24 The gene deletion approach was used in characterizing the physiological function of AKAP lbc (AKAP13), AKAP5, and AKAP15/18 (AKAP7). Ablation of AKAP13 was embryonically lethal, indicating that this AKAP was involved in genetic programming. 25 Deletion of the various isoforms of AKAP7 did not affect the responsiveness of cardiomyocytes to adrenergic stimulation. 26 (Figure 1) . 17, 22, 27, 28 Secondly, ablation of AKAP5 interfered . Ratios of heart-to-body weight. The data were plotted as means + SE and then compared among different groups. n, represents the number of mice in each condition. In (A), *P , 0.05 and ***P , 0.001 represent the P-value of either base in WT vs. base in KO mice or carvedilol in WT vs. carvedilol in KO. In (B), the P-value represents either base in WT vs. base in KO or carvedilol in WT vs carvedilol in KO mice.
Compromised cardiac function in AKAP5 KO mice with recycling of the agonist-internalized b 1 -AR in NMVM. 8 We believe that altered trafficking of the myocardial b 1 -AR and the role of CaN bound to AKAP5 in this phenomenon also plays a significant role in hypertrophy of AKAP5 2/2 mice. There is ample evidence that internalized b 2 -AR and other GPCR still signal intracellularly. 29, 30 Thus, retention of the agonist-internalized b 1 -AR might prolong the duration of G s -signalling in the heart of AKAP5 2/2 mice. Moreover, internalization was required for b 1 -AR-induced cardiac hypertrophy. 31 Consequently, enhanced hypertrophic signalling either from membrane-bound or internalized b 1 -AR could potentially contribute to hypertrophy in hearts of AKAP5 2/2 mice. The effects of AKAP5 in the heart were mediated by several mechanisms. Therefore, we used carvedilol, a third generation b-blocker, that acts by multiple mechanisms to ameliorate heart failure in humans. 10 These mechanisms involve blockade of a 1 -and b-AR, inhibition of reactive oxygen species, and biased agonism involving the activation of G protein receptor kinase/b-arrestin signalling. 10, 39 The mechanism underlying the beneficial effects of carvedilol in AKAP5 2/2 mice is not known, but might involve its ability to inhibit aberrant b 1 -AR, G proteindependent (G s -mediated), G protein-independent (Epac/b-arrestin), and numerous other kinases/phosphatases and their downstream signalling effectors in the heart. 15 
Differential resistance of AKAP5
